$15.66
-0.29-1.82%
Últ. Act.: Oct 23, 12:18 PM
Ultragenyx Pharmaceutical (RARE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Ultragenyx Pharmaceutical (RARE) publicó su última previsión de agosto 4, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $730M - $760M para el período.
En comparación con la previsión anterior, Ultragenyx Pharmaceutical mantenido redujo su previsión de ingresos desde un rango anterior de $730M - $760M.
Ultragenyx Pharmaceutical ha emitido 21 actualizaciones de orientación entre el febrero 16, 2023 y el agosto 4, 2026. During this period, the company raised its outlook 6 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.16 | $-1.48 | $-1.18 | $-1.22 |
| Actual | $-0.90 | $-1.84 | $-1.29 | $-1.81 |
| Surprise | +22.4% | -24.3% | -9.32% | -48.4% |
| Revenue | ||||
| Estimate | $182.5M | $159.0M | $202.3M | $167.1M |
| Actual | $214.0M | $136.0M | $207.0M | $159.9M |
| Surprise | +17.2% | -14.4% | +2.33% | -4.28% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.78 | $-0.54 | $-0.54 | $-0.05 |
| Revenue | ||||
| Consensus | $183.6M | $227.1M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $-0.90 | $-1.16 | 22.4 % |
| Q1 | May 5, 2026 | $-1.84 | $-1.48 | -24.3 % |
| Q4 | Feb 12, 2026 | $-1.29 | $-1.18 | -9.32 % |
| Q3 | Nov 4, 2025 | $-1.81 | $-1.22 | -48.4 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $214.00M | $182.53M | 17.2 % |
| Q1 | May 5, 2026 | $136.00M | $158.98M | -14.4 % |
| Q4 | Feb 12, 2026 | $207.00M | $202.28M | 2.33 % |
| Q3 | Nov 4, 2025 | $159.93M | $167.09M | -4.28 % |